Table 1.
Baseline features of our 276 patients
| Average ± SD (range) | Median | Patients n (%) | |
|---|---|---|---|
| Age years | 14.4 ± 3.1 (4–18) | 15 | |
| Pre puberty | 64 (23%) | ||
| During-after puberty | 212 (77%) | ||
| Gender | |||
| Male | 85 (31%) | ||
| Female | 191 (69%) | ||
| Familiarity for DTC | 42 (15%) | ||
| Thyroidectomy total | 276 (100%) | ||
| Lymphadenectomy central | 170 (62%) | ||
| Lymphadenectomy lateral | 102 (37%) | ||
| Decade of diagnosis of DTC | |||
| 1990–2000 | 68 (25%) | ||
| 2000–2010 | 88 (32%) | ||
| 2011–2020 | 120 (43) | ||
| Histotype | |||
| Papillary | 154 (58%) | ||
| Follicular variant of papillary | 59 (22%) | ||
| Follicular | 18 (6.6%) | ||
| Aggressive variant | 41 (15%) | ||
| Hurtle cell | 3 (1.1%) | ||
| NIFTP | 1 (0.4%) | ||
| Capsule invasion | 138 (50%) | ||
| Vascular invasion | 89 (32%) | ||
| Tumor size (mm) | 22 ± 14 (9–90) | 20 | |
| Multicentricity | 100 (37%) | ||
| Hashimoto thyroiditis | 64 (24%) | ||
| T-stage | |||
| sT1a | 40 (14%) | ||
| sT1b | 61 (22%) | ||
| sT2 | 80 (29%) | ||
| sT3 | 74 (27%) | ||
| sT4 | 19 (7%) | ||
| sTx | 2 (1%) | ||
| N-stage | |||
| sN0 | 105 (38%) | ||
| sN1a | 90 (33%) | ||
| sN1b | 81 (29%) | ||
| M-stage | |||
| sM0 | 236 (85%) | ||
| sM1 | 40 (15%) | ||
| Stage | |||
| sN1M1 | 26 (9%) | ||
| ATA class risk | |||
| Low | 84 (30%) | ||
| Intermediate | 141 (51%) | ||
| High | 51 (19%) | ||
| Previous RTT and/or CMT | 32 (11%) | ||
| Previous oncological disease | 34 (12%) | ||
| I131 therapy | 276 (100%) | ||
| TSH stimulation | |||
| Withdrawal | 247 (90%) | ||
| rhTSH | 29 (10%) | ||
| sTg at the time of ablation (ng/ml) | 92 ± 482 (0.04–5940) | 5.55 | |
| TgAb positive at ablation | 73/276 (26%) | ||
| First RAI activities administrated (GBq) | 2.6 ± 1.25 (1–7.4) | 2.7 | |
| Cumulative RAI activities administrated (GBq) | 9.6 ± 15.2 (1–53) | 3.7 | |
| N° radiometabolic therapies | 2 ± 1.9 (1–10) | 1 | |
| 1-year treatment response categories | |||
| Excellent response | 146 (53%) | ||
| Indeterminate response | 37 (13%) | ||
| Biochemical and/or structural incomplete response | 91 (33%) | ||
| na | 2 (1%) | ||
| Last disease status | |||
| NED | 241/276 (87%) | ||
| FU time months | 133 ± 100 (1–360) | 110 |
SD standard deviation, n number, GBq Gigabequerel, var variant, sTg stimulated thyroglobulin, Ab antibodies, na not available, NIFTP noninvasive follicular thyroid neoplasm with papillary-like nuclear features, RTT radiotherapy, CHT chemotherapy, RAI radioactive iodine, NED not evidence of disease, FU follow-up